A personalized approach to the management of rare genetic aberrations in oncology: A letter citing the EGFR exon 18 mutation molecular tumor board report-Reference-Cited by-同舟云学术

A personalized approach to the management of rare genetic aberrations in oncology: A letter citing the EGFR exon 18 mutation molecular tumor board report

Published:2024-01 Issue:1 Volume:7 Page:140-141
ISSN:2590-3233
Container-title:Cancer Research, Statistics, and Treatment
language:en
Short-container-title:

Author:

Pai Sanidhya¹,Varghese Ryan²

Affiliation:

1. Department of Biotechnology, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, India

2. Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph’s University, Philadelphia, PA, USA

Publisher

Medknow

Reference12 articles.

1. Identification of a rare EGFR exon 18 pathogenic variant in lung adenocarcinoma using targeted next-generation sequencing (NGS) as a tool for precision medicine;Jha;Cancer Res Stat Treat,2023

2. Liquid biopsy in lung cancer-hope or hype?;Choughule;Cancer Res Stat Treat,2019

3. Liquid biopsy in NSCLC: An investigation with multiple clinical implications;Bertoli;Int J Mol Sci,2023

4. Concordance of epidermal growth factor receptor mutation detection in bodily fluids other than blood with tissue biopsy: A retrospective analysis;Chougule;Cancer Res Stat Treat,2020

5. Outcomes with liquid biopsy to determine the EGFR mutation status in poor performance status, biopsy ineligible, advanced NSCLC patients;Pandey;Cancer Res Stat Treat,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Authors’ reply to Pai and Varghese, and Kenkre et al.;Cancer Research, Statistics, and Treatment;2024-01